Responders (n = 2337), n (%)/mean (SD) | Nonresponders (n = 2337), n (%)/Mean (SD) | p Valuea | |
---|---|---|---|
Inpatient hospitalization, n (%) with at least one visit | 149 (6.4%) | 297 (12.7%) | <0.001 |
Joint replacement surgeries, n (%) | 29 (1.2%) | 51 (2.2%) | 0.013 |
Infections, n (%) | 27 (1.2%) | 83 (3.6%) | <0.001 |
CV events, n (%) | 24 (1.0%) | 25 (1.1%) | 0.886 |
ED encounters, n (%) with at least one visit | 278 (11.9%) | 461 (19.7%) | <0.001 |
Outpatient visits, n (%) with at least one visit | 2334 (99.9%) | 2326 (99.5%) | 0.032 |
Physician office visit, n (%) | 2329 (99.7%) | 2324 (99.4%) | 0.274 |
Rheumatologist office visit, n (%) | 1706 (73.0%) | 1638 (70.1%) | 0.027 |
Physical/occupational therapy visits, n (%) | 390 (16.7%) | 512 (21.9%) | <0.001 |
DME claims, n (%) | 400 (17.1%) | 578 (24.7%) | <0.001 |
Imagingb claims, n (%) | 1676 (71.7%) | 1803 (77.2%) | <0.001 |
Pharmacy fills, n (%) with at least one fill | 2330 (99.7%) | 2331 (99.7%) | 0.781 |
Oral glucocorticoids | 1040 (44.5%) | 1463 (62.6%) | <0.001 |
Antihypertensives | 919 (39.3%) | 1017 (43.5%) | 0.004 |
Antidiabetics | 208 (8.9%) | 201 (8.6%) | 0.717 |
Antihyperlipidemics | 525 (22.5%) | 524 (22.4%) | 0.972 |
Antidepressives | 541 (23.1%) | 700 (30.0%) | <0.001 |
Pain medicationsc | 1542 (66.0%) | 1739 (74.4%) | <0.001 |
Number of pharmacy fills per patient, mean (SD) | 49.4 (29.44) | 50.9 (33.12) | 0.109 |
csDMARDs, n (%) with at least one fill | 1945 (83.2%) | 1937 (82.9%) | 0.755 |
Hydroxychloroquine | 504 (21.6%) | 538 (23.0%) | 0.232 |
Leflunomide | 219 (9.4%) | 277 (11.9%) | 0.006 |
Methotrexate | 1607 (68.8%) | 1596 (68.3%) | 0.729 |
Minocycline | 18 (0.8%) | 20 (0.9%) | 0.745 |
Sulfasalazine | 152 (6.5%) | 173 (7.4%) | 0.227 |
Biologics, n (%) with at least one fill | 2080 (89.0%) | 2088 (89.3%) | 0.706 |
Adalimumab | 586 (25.1%) | 840 (35.9%) | <0.001 |
Certolizumab pegol | 20 (0.9%) | 65 (2.8%) | <0.001 |
Etanercept | 1418 (60.7%) | 1512 (64.7%) | 0.004 |
Golimumab | 48 (2.1%) | 98 (4.2%) | <0.001 |
Infliximab | 8 (0.3%) | 14 (0.6%) | 0.200 |
Abatacept | 0 (0%) | 42 (1.8%) | <0.001 |
Anakinra | 0 (0%) | 3 (0.1%) | 0.083 |
Rituximab | 0 (0%) | 2 (0.1%) | 0.157 |
Tocilizumab | 0 (0%) | 7 (0.3%) | 0.008 |
Tofacitinib citrate | 0 (0%) | 13 (0.6%) | <0.001 |
Number of csDMARD pharmacy fills per patient, mean (SD) | 7.8 (6.14) | 7.1 (5.96) | <0.001 |
Number of biologic pharmacy fills per patient, mean (SD) | 9.5 (4.62) | 6.1 (4.25) | <0.001 |